HistCite - Record 30548: Clinical outcomes and insulin secretion after islet transplantation with the edmonton protocol

Author(s): Ryan EA; Lakey JRT; Rajotte RV; Korbutt GS; Kin T; Imes S; Rabinovitch A; Elliott JF; Bigam D; Kneteman NM; Wanock GL; Larsen I; Shapiro AMJ

Title: Clinical outcomes and insulin secretion after islet transplantation with the edmonton protocol

Source: DIABETES 50 (4): 710-719

Date: 2001 APR

Document Type: Journal : Article

DOI:

Language: English

LCR: 7 CR: 35 LCS: 115 GCS: 452 OCS:

Comment:

Address: Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada.
Univ Alberta, Dept Surg, Surg Med Res Inst, Edmonton, AB T6G 2S2, Canada.
Univ Alberta, Dept Med Microbiol & Infect Dis, Edmonton, AB T6G 2S2, Canada.
Capital Hlth Author, Edmonton, AB, Canada.

Reprint: Ryan, EA, Univ Alberta, Dept Med, 362 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.

E-mail:

Author Keywords:

KeyWords Plus: PANCREAS TRANSPLANTATION; GLUCOSE-TOLERANCE; DIABETES-MELLITUS; FOOT ULCERATION; RETINOPATHY; DACLIZUMAB; RECIPIENTS; INDUCTION; REJECTION; HUMANS

Abstract: Islet transplantation offers the prospect of good glycemic control without major surgical risks. After our initial report of successful islet transplantation, we now provide further data on 12 type 1 diabetic patients with brittle diabetes or problems with hypoglycemia previous to 1 November 2000. Details of metabolic control, acute complications associated with islet transplantation, and long-term complications related to immunosuppression therapy and diabetes were noted. Insulin secretion, both acute and over 30 min, was determined after intravenous glucose tolerance tests (IVGTTs). The median follow-up was 10.2 months (CI 6.5-17.4), and the longest was 20 months. Glucose control was stable, with pretransplant fasting and meal tolerance-stimulated glucose levels of 12.5 +/- 1.9 and 20.0 +/- 2.7 mmol/l, respectively, but decreased significantly, with posttransplant levels of 6.3 +/- 0.3 and 7.5 +/- 0.6 mmol/l, respectively (P < 0.006). All patients have sustained insulin production, as evidenced by the most current baseline C-peptide levels 0.66 0.06 nmol/l, increasing to 1.29 +/- 0.25 nmol/l 90 min after the meal-tolerance test. The mean HbA(1c) level decreased from 8.3 +/- 0.5% to the current level of 5.8 +/- 0.1% (P < 0.001). Presently, four patients have normal glucose tolerance, five have impaired glucose tolerance, and three have post-islet transplant diabetes two of whom need oral hypoglycemic agents and low-dose insulin (<10 U/day). Three patients had a temporary increase in their liver-function tests. One patient had a thrombosis of a peripheral branch of the right portal vein, and two of the early patients had bleeding from the hepatic needle puncture site; but these technical problems were resolved. Two patients had transient vitreous hemorrhages. The two patients with elevated creatinine levels pretransplant had a significant increase in serum creatinine in the long term, although the mean serum creatinine of the group unchanged. The cholesterol increased in five patients, and Lipid-lowering therapy was required for three patients. No patient has developed cytomegalovirus infection or disease, posttransplant lymphoproliferative disorder, malignancies, or serious infection to date. None of the patients have been sensitized to donor antigen. In 11 of the 12 patients, insulin independence was achieved after 9,000 islet equivalents (IEs) per kilogram were transplanted. The acute insulin response and the insulin area under the curve (AUC) after IVGTT were consistently maintained over time. The insulin AUC from the IVGTT correlated to the number of islets transplanted, but more closely correlated when the cold ischemia time was taken into consideration (r = 0.83, P < 0.001). Islet transplantation has successfully corrected labile type 1 diabetes and problems with hypoglycemia, and our results show persistent insulin secretion. After a minimum of 9,000 Ifs per kilogram are provided, insulin independence is usually attained. An elevation of creatinine appears to be a contraindication to this immunosuppressive regimen. For the subjects who had labile type 1 diabetes that was difficult to control, the risk-to-benefit ratio is in favor of islet transplantation.

Cited References:

BOULTON AJM, 1986, DIABETIC MED, V3, P335
BRENDEL M, 1999, INT ISLET TRANSPLANT, P1
BRUNZELL JD, 1976, J CLIN ENDOCR METAB, V42, P222
DAHLJORGENSEN K, 1985, BRIT MED J, V290, P811
DEMATTOS AM, 2000, AM J KIDNEY DIS, V35, P333
ECKHOFF DE, 2000, TRANSPLANTATION, V69, P1867
FABER OK, 1978, DIABETES, V27, P170
FARNEY AC, 2000, ANN SURG, V232, P696
GRUESSNER RWG, 1997, CLIN TRANSPLANT, V11, P299
HENDERSON JR, 1985, Q J EXP PHYSIOL CMS, V70, P347
HUMAR A, 2000, ANN SURG, V231, P269
KENDALL DM, 1990, NEW ENGL J MED, V322, P898
KINKHABWALA M, 1996, AM J SURG, V171, P516
KORBUTT GS, 1996, J CLIN INVEST, V97, P2119
KORC M, 1993, PANCREAS BIOL PATHOB, P751
KREIS H, 2000, TRANSPLANTATION, V69, P1252
KUMAR S, 1991, DIABETES RES CLIN PR, V13, P63
LAKEY JRT, 1995, TRANSPLANTATION, V59, P689
LAKEY JRT, 1999, CELL TRANSPLANT, V8, P285
LAURITZEN T, 1983, LANCET, V1, P200
LEVY JC, 1998, DIABETES CARE, V21, P2191
LIKE AA, 1970, AM J PATHOL, V59, P225
LINETSKY E, 1997, DIABETES, V46, P1120
RICORDI C, 1989, DIABETES, V38, P140
RICORDI C, 1990, ACTA DIABETOL LAT, V27, P185
RYAN EA, 1998, LANCET, V351, P1072
SERVICE FJ, 1970, DIABETES, V19, P644
SERVICE FJ, 1987, DIABETES CARE, V10, P225
SHAMOON H, 1993, NEW ENGL J MED, V329, P977
SHAPIRO AMJ, 2000, NEW ENGL J MED, V343, P230
SOUSA JEMR, 2000, CIRCULATION S, V102, P815
SUTHERLAND DER, 1998, TRANSPLANT P, V30, P1940
TEUSCHER AU, 1998, DIABETES, V47, P324
VASQUEZ EM, 2000, AM J HEALTH-SYST PH, V57, P437
VINCENTI F, 1998, NEW ENGL J MED, V338, P161